drugset / Trial / NCT01108393

Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder

NCT01108393

Phase 2 Completed 74 enrolled Servier
RandomizedParallel-groupDouble-blindTreatment

Summary

The study will evaluate the efficacy of agomelatine compared to placebo on the reduction of Obsessive and Compulsive symptoms after 16 weeks of treatment.

Timeline

Start
2010-05
Primary completion
2012-08
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Agomelatine Small molecule 25 mg Oral
Subject Agomelatine Small molecule 50 mg Oral